At least my visit to the ARQL meeting was of great interest--however, heading to the Sam Adams Brewery on Friday afternoon and finding that 99% of the college students in Boston had garnered all tour spots until 5:00, my friend and I detoured for Fenway Park. Having assisted the NY Yankees to victory during our annual meeting/baseball tour on Wednesday night, I’m afraid to admit that it appears the Boston Red Sox’s are a hopeless cause. The pregame action outside the gates of Fenway----cold beer, food and truly an eclectic crowd were the highlights---but trying to forget the overcrowded train we took back to Woburn. As has been mentioned here by others who attended—the meeting was brief, but CEO and board members were upbeat and positive. Key take- a-ways for me- 1) ARQL drug works independent of being a cohort dosing protocol 2) Distinct impression (for me) that new drug candidate from ARQL platform is nearing fruition, thus, opening potential of new partnership deal. 3) Management pleased that 1,000 patient enrollment completed in such a timely manner 4) More definitive data will be forthcoming at ASCO next week 5) First read out for the MARQUEE trial ‘should’ happen by end of year, but they did give themselves some wiggle room on this event. 6) When question of takeover was asked, they gave the expected answer, but I did note that the CEO was smiling broadly while the Chairman offered up his pro forma response to such sensitive information. The CEO had just mentioned that he held more than 600,000 shares, so maybe he was grinning in that he had done a quick mental math exercise as to what a buyout would mean. I don’t expect a buyout in the near term; however, my investment philosophy does factor in the potential of such events happening. I’ve already had one of my biotech holdings taken out this year (MITI), and I see parallels in ARQL. Time will tell! (IMO) Gentlemen who posed most of the questions---good job and on point questions! My one question and the clarification statement I offered about the history of the NIH seems now to have put me into batting last, but then I think I could still help the Red Sox with their hitting woes. Next few months should be interesting—now if we could only get some buyers at our backs and stop their current effort to slow our boat.